Nature Reviews Drug Discovery 9, 584 (2010). doi:10.1038/nrd3245
Phase III trial results for ipilimumab, an immunomodulatory monoclonal antibody that targets cytotoxic T-lymphocyte antigen 4 (CTLA4), showed that it increased survival by 3.7 months in patients with advanced melanoma
(N. Engl. J. Med. 14 Jun 2010; doi:10.1056/NEJMoa1003466).âThese findings are appropriately receiving (Source: Nature Reviews Drug Discovery)
MedWorm Message: Register for MedMatcha, MedWorm's medical advertising network, and receive $5 free advertising.
Read more...

